Amyotrophic Lateral Sclerosis: New Developments in Diagnostic Markers

There is an intensive search for diagnostic markers in amyotrophic lateral sclerosis (ALS). Protein analysis (proteomics) of the cerebrospinal fluid (CSF) appears particularly promising using mass spectrometry and 2-D gel electrophoresis to detect low and high molecular weight proteins, respectively. It is open whether protein changes specific for ALS will be found. This also holds true for inflammatory proteins such as the cytokine monocyte chemoattractant protein-1 which has been detected in CSF in ALS and for other cytokines such as interleukin-1β. Increases of the protein Nogo A and B in muscle tissue and decreases of the growth factor vascular endothelial growth factor in blood may also be useful for monitoring the course of ALS. Clinical neurophysiology provides markers for upper and lower motor neuron damage. A very sensitive method to detect early upper motor neuron involvement is the transcranial magnetic stimulation modification ‘triple stimulation technique’ which can show significant changes in patients without clinical upper motor neuron signs. The loss of lower motor neurons can be closely monitored by MUNE techniques (motor unit number estimate). In modern imaging, the MRI technique DTI (diffusion tensor imaging) has the greatest diagnostic potential for ALS. It can separate between normal and ALS in group comparisons and may be improved to be diagnostic in individual patients. Voxel-based morphometry can reliably demonstrate regional cortical atrophy in motor areas and beyond although it is not appropriate for use in individual patients.

[1]  M A Horsfield,et al.  Diffusion tensor MRI assesses corticospinal tract damage in ALS , 1999, Neurology.

[2]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[3]  K. Markides,et al.  Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography‐Fourier transform ion cyclotron resonance mass spectrometry , 2004, Proteomics.

[4]  W. Robberecht,et al.  Minocycline delays disease onset and mortality in a transgenic model of ALS , 2002, Neuroreport.

[5]  S. Hesse,et al.  Amyotrophic lateral sclerosis: Macro–EMG and twitch forces of single motor units , 1990, Muscle & nerve.

[6]  C. Duyckaerts,et al.  Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions , 2004, Acta Neuropathologica.

[7]  G. Deuschl,et al.  Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration , 2003, Journal of Neuroimmunology.

[8]  S. Hesse,et al.  Collateral nerve sprouting and twitch forces of single motor units in conditions with partial denervation in man , 1989, Neuroscience Letters.

[9]  H. Mitsumoto,et al.  Amyotrophic lateral sclerosis: Objective upper motor neuron markers , 2002, Current neurology and neuroscience reports.

[10]  J. Valentine,et al.  Misfolded CuZnSOD and amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Magistris,et al.  Transcranial stimulation excites virtually all motor neurons supplying the target muscle. A demonstration and a method improving the study of motor evoked potentials. , 1998, Brain : a journal of neurology.

[12]  M. Schwab,et al.  Nogo and its paRTNers. , 2003, Trends in cell biology.

[13]  M. Magistris,et al.  Quantification of upper motor neuron loss in amyotrophic lateral sclerosis , 2000, Clinical Neurophysiology.

[14]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[15]  A. Kossev,et al.  Triple stimulation technique (TST) in amyotrophic lateral sclerosis , 2004, Clinical Neurophysiology.

[16]  V. Pasqua,et al.  Changes in motor unit numbers in patients with ALS: a longitudinal study using the adapted multiple point stimulation method , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[17]  Christoph Schmitz,et al.  Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS , 2005, Nature Neuroscience.

[18]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[19]  R. Dengler,et al.  Amyotrophic Lateral Sclerosis and Related Disorders , 2004 .

[20]  K. Ikeda,et al.  MRI in patients with amyotrophic lateral sclerosis: correlation with clinical features. , 1991, The International journal of neuroscience.

[21]  M. Swash,et al.  Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[22]  R. Dengler.  Current treatment pathways in ALS: a European perspective. , 1999, Neurology.

[23]  M. Swash,et al.  Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[24]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[25]  E. T. Bullmore,et al.  Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS , 2001, Neurology.

[26]  C Fellner,et al.  MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1- and proton-density-weighted images , 2001, Journal of the Neurological Sciences.

[27]  R. Olney,et al.  Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis , 1997, Neurology.

[28]  Ole Gredal,et al.  Corticospinal tract degeneration and possible pathogenesis in ALS evaluated by MR diffusion tensor imaging , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[29]  J. Hauw,et al.  Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity , 2005, Annals of neurology.

[30]  Minh N. H. Nguyen,et al.  Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin‐1β in neurodegeneration , 2001, Annals of neurology.

[31]  Volkmar Glauche,et al.  Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. , 2004, Brain : a journal of neurology.

[32]  I D Wilkinson,et al.  Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS , 2004, Neurology.

[33]  C Fellner,et al.  Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: A follow-up examination including FLAIR images , 2002, Journal of the Neurological Sciences.

[34]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[35]  M. Bromberg,et al.  Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis , 1993, Muscle & nerve.